SPOTLIGHT Study

About Smoldering Multiple Myeloma

Smoldering multiple myeloma is a disorder that affects the blood and bone marrow, causing abnormal plasma cells to build up in the blood. It is not yet considered cancer, but can progress to multiple myeloma.

A diagnosis of smoldering multiple myeloma increases the risk of multiple myeloma.
Smoldering multiple myeloma affects 1 in 200 people.
Patients with smoldering multiple myeloma may not have any symptoms. It is usually diagnosed with other health conditions.
Drugs being tested in clinical trials for patients with high-risk smoldering multiple myeloma may lead to side effects. They also may not be effective or necessary.

About the SPOTLIGHT Study

Study Goals

Provide data on patients with high-risk smoldering multiple myeloma not receiving therapy. With this data, we hope to better understand:

Complications related to multiple myeloma
Quality of life for patients
Whether drug therapy is necessary

Eligibility Criteria

Age 18 or older
Diagnosed with high-risk smoldering multiple myeloma within the past year

Why Join the Study?

This trial is strictly observational. We hope the SPOTLIGHT study will show that patients, like you, can be safely monitored and avoid treatment.

Your Role as a Patient

Assessments will take place during your normal clinic visits. You won’t need to make extra trips.
You will continue to receive an MRI approximately every six months (per standard care) to look closely at your bones for signs of myeloma.
You will be asked to complete a 15-minute Quality of Life questionnaire every six months.